Absci Shares Jump 22% on Hair‑Loss Market Optimism

Absci Corp shares jumped 22.2% to $4.815 in early trading after KeyBanc highlighted hair‑loss market optimism.
KeyBanc estimates a >$40 billion hair‑loss treatment market and maintains a $9 price target for Absci.
Absci’s experimental drug ABS‑201, requiring two‑three injections over six months, could complement existing therapies rather than compete.
Nektar Therapeutics reported its injection stimulated hair regrowth in alopecia areata patients, renewing investor interest.